A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron^® (Peginterferon alfa-2b) and Actimmune^® (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer.

ABSTRACT:

Background

Ovarian cancer has no definitive second line therapeutic options, and largely recurs in the peritoneal cavity. Locoregional immune therapy using both interferons and monocytes can be used as a novel approach. Interferons have both cytostatic and cytotoxic properties, while monocytes stimulated with interferons have potent cytotoxic properties. Due to the highly immune suppressive properties of ovarian cancer, ex vivo stimulation of autologous patient monocytes with interferons and infusion of all three agents intraperitoneally (IP) can provide a strong pro-inflammatory environment at the site of disease to kill malignant cells.

Methods

Patient monocytes are isolated through counterflow elutriation and stimulated ex vivo with interferons and infused IP through a se

SUBMITTER: Green DS 

PROVIDER: S-EPMC6048715 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature